FDA Approves Edwards EVOQUE® Tricuspid Valve Replacement System

The U.S. Food and Drug Administration (“FDA”) recently approved the Edwards EVOQUE®  Tricuspid Valve Replacement System (the “EVOQUE® system”) for use in treating Tricuspid Regurgitation (“TR”). The EVOQUE®  system is designed to replace the native tricuspid valve in patients suffering from severe TR without the need for conventional open-heart surgery, according to the system’s Instructions For Use….
By: Knobbe Martens
Previous Story

USPTO: AI Use in Invention Process Does Not Foreclose Patentability

Next Story

Bad Medicine: 5 Lessons from the Connecticut AG’s Report on CTDPA Cure Notices